Clinical Collaboration Centauri is advancing lead candidates CTX-187 toward an early-stage clinical trial and ABX-01 in the same program, creating multiple near-term licensing or co-development opportunities for pharma and biotech partners. Potential engagements include joint development, manufacturing collaborations, and regulatory strategy support to accelerate clinical progress.

Platform Licensing The Alphamer platform enables antibody recruitment by linking aptamer-based targets with epitopes, offering a pathway to license the platform or pursue co-development deals with infectious disease players seeking novel antimicrobial modalities. Strong IP position supports structured licensing discussions.

AMR Funding Momentum Recent investor activity and AMR-focused funding backing Centauri signal readiness to collaborate on funded R&D initiatives, co-development, and milestone-driven partnerships, with potential access to grant programs and non-dilutive funding alongside strategic investments.

Asset Momentum With ABX-01 driving a broad-spectrum antimicrobial program and CTX-187 advancing, there are opportunities for contract research, manufacturing, and early-clinical services partners to engage in non-dilutive or milestone-based collaborations to accelerate development.

UK Agility Based in the UK with a lean team and a strong innovation ecosystem, Centauri offers attractive collaboration opportunities for European and global partners, leveraging local CROs, manufacturing networks, academia, and government incentives for accelerated development.